Antibodies against Epstein-Barr virus (EBV)

BIOCHIP Sequence EBV

  • Gold standard for the determination of antibodies against the EBV-CA antigens (Epstein-Barr virus capsid antigen), EBV-EA (Epstein-Barr early antigen) and EBNA (Epstein-Barr nuclear antigen).
  • Indication: infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma (NPC).
  • IgG antibodies against EBV-CA indicate an EBV infection. An at least twofold increase in titer and the absence of antibodies against EBNA at the same time is characteristic for the early phase of the infection. IgM antibodies against EBV-CA and antibodies against EBV-EA can also be found in acute infections, but they do not necessarily always occur. The presence of antibodies against EBNA generally indicates the late phase of an EBNA infection.
  • In cases of an acute EBV infection which cannot be reliably discriminated from a relapse or reinfection, the determination of the antibody avidity using a modified immunofluorescence test as an additional parameter is useful. This requires an additional incubation with urea solution (ZF 1130-0801). The determination of low-avidity antibodies against EBV-CA indicates an acute infection.
  • For the monospecific confirmation of EBV-CA antibodies in the same test procedure the BIOCHIP containing ECV-CA is supplemented with the antigen substrates gp125 antigen (native) and p19 antigen (recombinant) (EUROPLUS FI 2791-####-20 G or M).
  • For highly differentiated diagnostics the BIOCHIP Sequence EBV (FI 2799-####-1 X) can be supplemented by using  the antigens gp125 and p19 (EUROPLUS FI 2799-####-21 X).
  • Due to the high prevalence of anti-EBV-CA IgA in NPC patients, the parameter is well suited for screening. Confirmation of the result by determination of IgA antibodies against EBV-EA is recommended. Further anti-EBV test kits for indirect immunofluorescence.

ProductOrder number
Anti-EBV-CA IIFT (IgA / IgG / IgM) FI 2791 A / G / M
Anti-EBV-EA IIFT (IgA / IgG) FI 2795 A / G
Anti-EBNA IIFT (IgG) FI 2793 C
Anti-EBV-CA / EBV-EA IIFT (IgA / IgG / IgM) FI 2791-2 A / G / M

Anti-EBV-CA, anti-EBNA-1, anti-EBV-EA

Incubated Anti-EBNA-1 ELISA
  • Specific confirmatory test for antibodies against EBV-CA, EBNA-1 or EBV-EA.
  • Indications: infectious mononucleosis, Burkitt-lymphoma, nasopharyngeal carcinoma.
  • Serum dilution 1 : 101; conjugate class anti-IgA, -IgG or IgM, POD-labelled.
  • 1-point calibration, semi-quantitative (IgA, IgM) or 3-point calibration, quantitative (IgG). Identical incubation conditions and times: all tests can be combined without difficulty on one and the same microplate.
  • EBV-CA: native antigen, purified by affinity chromatography; EBNA-1 and EBV-EA: recombinant antigen.
  • IgM test kit includes IgG/RF absorbent in sample buffer for IgG absorption in preparation for the determination of specific IgM class antibodies.
  • Available individual ELISA:

To top

ProductOrder number
Anti-EBV-CA ELISA (IgA / IgG / IgM)EI 2791 A / G / M
Anti-EBNA-1 ELISA (IgG)EI 2793 G
Anti-EBV-EA ELISA (IgA / IgG / IgM)EI 2795 A / G / M

EUROLINE: EBV Profile 2

Incubated EUROLINE EBV Profile 2
  • Differentiation of antibodies against Epstein-Barr virus antigens.
  • Indications: infectious mononucleosis, Burkitt-lymphoma, nasopharyngeal carcinoma.
  • Serum dilution 1 : 51; conjugate class anti-human IgG or IgM, AP-labelled.
  • With the EUROLINE EBV Profile 2, five different antibodies can be determined: antibodies against, VCA p19, EBNA-1, p22, EA-D.
  • Recombinant antigens (exception: VCA gp125, native, purified by affinity chromatography).
  • EBNA-1 (IgG) negative und VCA (IgG and IgM) positive: acute (fresh) infection.
  • EBNA-1 (IgG) and VCA (IgG) positive and VCA (IgM) negative: late phase of infection.
  • EBNA-1 (IgG) negative, but band p22 (IgG) and VCA (IgG) positive: late phase of infection with loss of anti-EBNA-1.
  • Test strips can be automatically incubated and evaluated using the systems EUROBlotMaster, EUROBlotOne, and EUROLineScan.

To top

ProductOrder number
EUROLINE Anti-EBV Profile 2 (IgG / IgM)DN 2790-2 G / M

Westernblot: anti-EBV

Incubated Westernblot Anti-EBV.
  • Specific confirmatory test for the detection of antibodies against Epstein-Barr virus antigens, differentiation of antibodies against Epstein-Barr virus antigens.
  • Indications: infectious mononucleosis, Burkitt-lymphoma, nasopharyngeal carcinoma.
  • Serum dilution 1 : 51; conjugate class anti-IgG or anti-IgM, AP-labelled.
  • Antigens: whole antigen, SDS extract.
  • Bands from all specific antigens are included and clearly separated.
  • EBNA-1 (IgG) negative und VCA (IgG and IgM) positive: acute (fresh) infection.
  • EBNA-1 (IgG) and VCA (IgG) positive and VCA (IgM) negative: late phase of infection.
  • EBNA-1 (IgG) negative, but band p22 (IgG) and VCA (IgG) positive: late phase of infection with loss of anti-EBNA-1.
  • Test strips can be automatically incubated and evaluated using the systems EUROBlotMaster, EUROBlotOne, and EUROLineScan.

ProductOrder number
 Anti-EBV Westernblot (IgG / IgM) DY 2790 G / M

To top